Lehrstuhl für Biochemie und Molekulare Medizin

ROS is the boss (2017) Hahn J, Kienhofer D, Stoof J, Csepregi JZ, Reinwald C, Maueröder C, Urbonaviciute V, et al. Conference contribution Bone Tissue Engineering Under Xenogeneic-Free Conditions in a Large Animal Model as a Basis for Early Clinical Applicability (2017) Weigand A, Beier J, Schmid R, Knorr T, Kilian D, Goetzl R, Gerber T, et al. Journal article Effect of melanoma cells on proliferation and migration of activated hepatic stellate cells in vitro (2017) Meyer T, Koch A, Ebert EV, Czech B, Mueller M, Boßerhoff AK, Lang SA, Hellerbrand C Journal article Investigation of toxicity and mutagenicity of cold atmospheric argon plasma (2017) Maisch T, Boßerhoff AK, Unger P, Heider J, Shimizu T, Zimmermann JL, Morfill GE, et al. Journal article Cold atmospheric plasma (CAP) activates angiogenesis-related molecules in skin keratinocytes, fibroblasts and endothelial cells and improves wound angiogenesis in an autocrine and paracrine mode (2017) Arndt S, Unger P, Berneburg M, Boßerhoff AK, Karrer S Journal article Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype (2017) Minakaki G, Menges S, Kittel A, Emmanouilidou E, Schäffner I, Barkovits K, Bergmann A, et al. Journal article CRIP1a inhibits endocytosis of G-protein coupled receptors activated by endocannabinoids and glutamate by a common molecular mechanism (2017) Mascia F, Klotz L, Lerch J, Ahmed MH, Zhang Y, Enz R Journal article Usability and Suitability of the Omics-Integrating Analysis Platform tranSMART for Translational Research and Education (2017) Christoph J, Knell C, Boßerhoff AK, Naschberger E, Stürzl M, Rübner M, Seuß H, et al. Journal article Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells (2017) Uslu U, Schliep S, Schliep K, Erdmann M, Koch HU, Parsch H, Rosenheinrich S, et al. Journal article Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition (2017) Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Boßerhoff AK Journal article